Evaluation of the Cryopreserved Amniotic Membranes in the Care of Resistant Vascular Ulcers (MAUV)

To evaluate tolerance and efficiency of cryopreserved amniotic membranes in local treatment of resistant vascular ulcers. To evaluate complete cicatrisation, efficiency on pain, prevention of infection, improvement of quality of life. To evaluate rate of amputations and recurrence at one year after complete cicatrisation

Treatment of patients suffering from vascular ulcers or amputation's wound from at least 6 months after or without possibility for surgical treatment. A cryopreserved amniotic membrane, obtained after caesarean from consenting women without any disease, is applied on the ulcer after serological checking and changed once a week. Main criterias: Tolerance will be evaluated on clinical criterias. Efficiency will be evaluated by measuring reduction of ulcer's area (reduction of at least 50 % at 6 months). Secondary criterias: Reduction of pain will be evaluated by analogic visual scale and evaluation of analgesic consumption. Evaluation of infections, amputations, complete healing, improvement of quality of life by SF36 questionnaire and recurrence at one year for patients with complete healing.

The amniotic membrane is taken with a sterile crowbar then applied side foetal face against the ulcer and displayed in a homogeneous way

Inclusion Criteria: Obtained informed consent Leg or foot arterial or mixed ulcer older than at least 3 months Exclusion Criteria: No obtained informed consent Possibility for surgical treatment (revascularisation) Age less than 18 Pregnancy Indication for major amputation (below /above the knee) Venous ulcer Ulcer with infection and / or necrosis Mycotic ulcer